Practolol
{{Drugbox | Verifiedfields = changed | verifiedrevid = 464212885 | IUPAC_name = (RS)-N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide | image = Practolol structure.png | width = 250
| tradename =
| CASNo_Ref = 
| CAS_number_Ref =
| CAS_number = 6673-35-4
| ATC_prefix = C07
| ATC_suffix = AB01
| PubChem = 4883
| IUPHAR_ligand = 555
| DrugBank_Ref =
| DrugBank = DB01297
| ChemSpiderID_Ref =
| ChemSpiderID = 4715
| UNII_Ref =
| UNII = SUG9176GRW
| KEGG_Ref = 
| KEGG = D05587
| ChEBI_Ref =
| ChEBI = 258351
| ChEMBL_Ref =
| ChEMBL = 6995
| C=14 | H=22 | N=2 | O=3
| molecular_weight = 266.336 g/mol
| smiles = O=C(Nc1ccc(OCC(O)CNC(C)C)cc1)C
| InChI = 1/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
| InChIKey = DURULFYMVIFBIR-UHFFFAOYAT
| StdInChI_Ref =
| StdInChI = 1S/C14H22N2O3/c1-10(2)15-8-13(18)9-19-14-6-4-12(5-7-14)16-11(3)17/h4-7,10,13,15,18H,8-9H2,1-3H3,(H,16,17)
| StdInChIKey_Ref =
| StdInChIKey = DURULFYMVIFBIR-UHFFFAOYSA-N
}}
|
WikiDoc Resources for Practolol |
|
Articles |
|---|
|
Most recent articles on Practolol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Practolol at Clinical Trials.gov Clinical Trials on Practolol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Practolol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Practolol Discussion groups on Practolol Directions to Hospitals Treating Practolol Risk calculators and risk factors for Practolol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Practolol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Practolol (Eraldin, Dalzic, Praktol, Cardiol, Pralon, Cordialina, Eraldina, Teranol) is a selective beta blocker that has been used in the emergency treatment of cardiac arrhythmias. Practolol is no longer used as it is highly toxic despite the similarity of its chemical formula to propranolol. After its introduction, keratoconjunctivitis sicca, conjunctival scarring, fibrosis, metaplasia, and shrinkage developed in 27 patients as an adverse reaction to practolol. Rashes, nasal and mucosal ulceration, fibrous or plastic peritonitis, pleurisy, cochlear damage, and secretory otitis media also occurred in some cases. Three patients suffered profound visual loss though most retained good vision. Symptoms and signs improved on withdrawal of the drug, but reduction of tear secretion persisted in most patients. (British Medical Journal, March 15, 1975)
Side Effects
Side effects are similar to those of other beta blockers, such as bronchoconstriction, cardiac failure, cold extremities, fatigue and depression, hypoglycaemia.[1]
Furthermore, chronic use of practolol may cause oculomucocutaneous syndrome,[1] a severe syndrome whose signs include conjunctivitis sicca and psoriasiform rashes, otitis and sclerosing serositis. This syndrome has not been observed with other such beta blockers.[2]
Ban
This drug has been withdrawn from the market in India due to Oculomucocutaneous Syndrome.[3]
External Links
- Scientific information / studies
- Guinea Pig study from 1975
- Liver effect study from 1981
- Study of uses during surgery
- Molecular structure
- General information
References
- ↑ 1.0 1.1 Rod Flower; Humphrey P. Rang; Maureen M. Dale; Ritter, James M. (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-06911-5.
- ↑ rxmed.com > Nadolol Retrieved on July, 2010.
- ↑ "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Retrieved 2013-09-17.